New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - morphine sulfate pentahydrate 20mg - film coated tablet - 20 mg - active: morphine sulfate pentahydrate 20mg excipient: hypromellose lactose macrogol 400 magnesium stearate opaspray pink m-1-5503 povidone pregelatinised maize starch purified talc purified water - sevredol tablets are indicated for the relief of both acute and chronic severe pain in adults and children aged three years and above.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - leuprorelin acetate 7.5mg (includes 10.2mg leuprorelin acetate to deliver 7.5mg leuprorelin);  ;  ; leuprorelin acetate 7.5mg (includes 10.6mg leuprorelin acetate to deliver 7.5mg leuprorelin) - injection with diluent - 7.5 mg - active: leuprorelin acetate 7.5mg (includes 10.2mg leuprorelin acetate to deliver 7.5mg leuprorelin)     excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 7.5mg (includes 10.6mg leuprorelin acetate to deliver 7.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - leuprorelin acetate 22.5mg (includes 28.2mg leuprorelin acetate to deliver 22.5mg leuprorelin);  ;  ; leuprorelin acetate 22.5mg (includes 29.2mg leuprorelin acetate to deliver 22.5mg leuprorelin) - injection with diluent - 22.5 mg - active: leuprorelin acetate 22.5mg (includes 28.2mg leuprorelin acetate to deliver 22.5mg leuprorelin)     excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 22.5mg (includes 29.2mg leuprorelin acetate to deliver 22.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - leuprorelin acetate 30mg (includes 35.8mg leuprorelin acetate to deliver 30mg leuprorelin);  ;  ; leuprorelin acetate 30mg (includes 37.2mg leuprorelin acetate to deliver 30mg leuprorelin) - injection with diluent - 30 mg - active: leuprorelin acetate 30mg (includes 35.8mg leuprorelin acetate to deliver 30mg leuprorelin)     excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 30mg (includes 37.2mg leuprorelin acetate to deliver 30mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - leuprorelin acetate 45mg (includes 56.3mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin);  ;  ; leuprorelin acetate 45mg (includes 59.2mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin) - injection with diluent - 45 mg - active: leuprorelin acetate 45mg (includes 56.3mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin)     excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 45mg (includes 59.2mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - dorzolamide hydrochloride 22.26 mg/ml equivalent to 20 mg/ml dorzolamide free base; timolol maleate 6.83 mg/ml equivalent to 5 mg/ml timolol free base - eye drops, solution - 20mg/ml, 5mg/ml - active: dorzolamide hydrochloride 22.26 mg/ml equivalent to 20 mg/ml dorzolamide free base timolol maleate 6.83 mg/ml equivalent to 5 mg/ml timolol free base excipient: benzalkonium chloride hyetellose mannitol sodium citrate sodium hydroxide water for injection - cosopt is indicated for the treatment of elevated intraocular pressure (iop) in patients with: · ocular hypertension · open-angle glaucoma · pseudoexfoliative glaucoma · or other secondary open-angle glaucoma's and who are: · insufficiently responsive to topical beta blocker monotherapy · currently receiving concomitant antiglaucoma therapies such as dorzolamide hcl and timolol maleate

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - timolol maleate 3.42 mg/ml equivalent to 2.5 mg/ml timolol - eye drops, solution - 0.25 % - active: timolol maleate 3.42 mg/ml equivalent to 2.5 mg/ml timolol excipient: benzalkonium chloride as 17% solution dibasic sodium phosphate monobasic sodium phosphate dihydrate sodium hydroxide as 1n solution to ph 6.8-7.0 water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - timolol maleate 6.84 mg/ml equivalent to 5 mg/ml timolol - eye drops, solution - 0.5 % - active: timolol maleate 6.84 mg/ml equivalent to 5 mg/ml timolol excipient: benzalkonium chloride as 17% solution dibasic sodium phosphate monobasic sodium phosphate monohydrate sodium hydroxide as 1n solution to ph 6.8-7.0 water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - palonosetron hydrochloride 50 µg/ml - solution for injection - 250µg/5ml - active: palonosetron hydrochloride 50 µg/ml excipient: citric acid monohydrate disodium edetate dihydrate hydrochloric acid mannitol sodium citrate dihydrate sodium hydroxide water for injection - aloxi is indicated for prevention of nausea and vomiting induced by cytotoxic chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - dihydrocodeine hydrogen tartrate 60mg equivalent to dihydrocodeine 40 mg - modified release tablet - 60 mg - active: dihydrocodeine hydrogen tartrate 60mg equivalent to dihydrocodeine 40 mg excipient: cetostearyl alcohol hyetellose lactose monohydrate magnesium stearate purified talc - dhc continus is indicated for the management of severe pain where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and -the pain is opioid-responsive, and -requires daily, continuous, long term treatment. dhc continus is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. dhc continus is not indicated as an as-needed (prn) analgesia.